WORLD HEALTH ORGANIZATION

Researchers at CRCHUM will launch the RESTART trial this fall to test whether fostemsavir can improve cardiovascular health in HIV patients by targeting the toxic viral protein gp120.

The World Health Organization reports a concerning decrease in antibacterial agents under development, dropping from 97 in 2023 to 90 in 2025, with only 15 qualifying as innovative treatments.

Recce Pharmaceuticals has begun patient dosing in its registrational Phase 3 clinical trial of RECCE® 327 Topical Gel for diabetic foot infections in Indonesia, targeting up to 310 patients across five clinical sites.

Globe Biotech Limited has obtained the first US pharmaceutical patent in Bangladesh's 54-year history for its COVID-19 vaccine Bangavax, marking a significant milestone for the country's pharmaceutical industry.

A large UK retrospective study of 624,308 adults found that metformin initiated within 90 days of COVID-19 infection reduced Long COVID risk by 64% in overweight or obese individuals.

The World Health Organization has added GLP-1 medications including semaglutide and tirzepatide to its essential medicines list for treating type 2 diabetes with comorbidities.

A joint research team from King Abdulaziz City for Science and Technology and the University of California, San Diego, has developed a breakthrough smart multi-compartment capsule that delivers multiple medications throughout the day using programmed release mechanisms.

Researchers at Mount Sinai identified three powerful monoclonal antibodies targeting the A35 viral protein that completely prevented death and protected rodents from severe mpox disease in laboratory studies.

ImmunityBio has initiated a Phase 2 study evaluating ANKTIVA (nogapendekin alfa inbakicept-pmln) as a potential treatment for long COVID, marking the first clinical trial of an IL-15 agonist for this indication.

Gilead Sciences' HIV prevention drug Yeztugo is performing "well ahead of expectations" following its recent US and European launch, with unaided awareness reaching 72% compared to typical industry launch levels.